AstraZeneca Plc.

AstraZeneca is a international pharmaceutical and biological research company based in London. It is the 7th largest pharma company in the world and is also listed in the New York an OMX Swedish-Finnish stock exchanges.

AstraZeneca is the combination of the 1913 Astra AB company which was founded in Sweden by 400 doctors and apothecaries and the Zeneca Group which spun-off from ICI i 1993. The two companies merged in 1999 to form AstraZeneca.

AstraZeneca has formed many strategic alliances in the pharma sector including alliances with Bristol-Myers Squibb and Abbott Laboratories. In 2006 is acquired Cambridge Antibody Technology.

AstraZeneca employs around 11,000 people in the UK with 4,500 based in the Alderley Park research centre. Another 4,000 people are employed in Sweden.

AstraZeneca Key Products

AstraZeneca is a leader in researching and producing medicines in these areas:

  • Gastrointestinal
  • Cardiac and vascular
  • Neurological and psychiatric
  • Infection
  • Respiratory
  • Pathological inflammation
  • Oncology

Company Information

AstraZeneca is a private limited company registered in England and Wales under company number 03674842.

AstraZeneca (Headquarters)

Company Registrar

  • Equiniti Limited
  • Aspect House
  • Spencer Road
  • Lancing
  • West Sussex
  • BN99 6DA
  • Tel: (in UK) 0800 389 1580
  • Tel: (outside UK) +44 (0)121 415 7033
  • www.shareview.co.uk

AstraZeneca Dividend Payments

Dividends are paid twice a year, with a greater proportion paid as a second interim. The first payment is made in September and the second in March.

View AstraZeneca dividend history here: www.astrazeneca.com/Investors/Investor-tools/Dividend-calculator

 

 

  6 comments for “AstraZeneca Plc.

  1. SHP
    February 2, 2012 at 4:49 pm

    The GMB Union has said 250 to 300 of the cuts will be in R&D at the firm’s site at Alderley Park, Cheshire. – Source: BBC News.

    As well as research and development cuts there are also likely to be cuts to administration staff in various other locations.

    The reason for the cuts is a fall in profits in the last 3 months of 2011 to £1.32bn.

  2. SHP
    February 2, 2012 at 9:02 am

    Astrazeneca annouce global job cuts. In region of 7000 globally, unknown how many in the UK.

  3. SHP
    December 20, 2011 at 10:46 am

    Astrazeneca shareholders are selling out on the news that 2 of its new drugs this year have failed to take off this year. Share price is dropping sharply today.

  4. SHP
    June 2, 2011 at 2:51 pm

    AstraZeneca and Heptares Therapeutics are working together on a range of new medicines based on targeting G-protein couple receptors GPCR. This research is aimed at providing treatments for neuro-muscular conditions, cardiovascular and inflammation related conditions.

    AstraZeneca is paying $6.25 million for the rights to market the products. Hepatares has also made deals with Shire and Takeda.

    Visit http://www.heptares.com/ to learn more about their research and their partnerships. Their research was recently published in Nature.

  5. SHP
    May 24, 2011 at 4:51 pm

    AstraZeneca have made a partnership with Daiichi Sankyo in Japan to market Amgen, a new drug which treats bone cancer.

    Daiichi owns the rights to Amgen.

  6. CityAnalyst
    May 23, 2011 at 5:36 pm

Leave a Reply

Your email address will not be published. Required fields are marked *